Literature DB >> 15908751

Inhibiting long-chain fatty acyl CoA synthetase does not increase agonist-induced release of arachidonate metabolites from human endothelial cells.

Margaret T Weis1, Monica Brady, Mike Moore, Jason Crumley, John N Stallone.   

Abstract

BACKGROUND: Triacsin C, a fatty acid analog, inhibits endothelial nitric oxide synthetase (eNOS) palmitoylation, increases nitric oxide synthesis and enhances methacholine-induced relaxation of vascular rings. The experiments presented here tested the hypothesis that triacsin C increases the synthesis of PGI(2) and/or endothelial-derived hyperpolarizing factor.
METHODS: Long-chain fatty acyl CoA synthetase activity (LCFACoAS), agonist-induced prostacyclin synthesis and agonist-induced release of radioactivity in endothelial cells labeled with [(3)H]arachidonic acid were measured in the presence and absence of triacsin C.
RESULTS: Inhibition by triacsin C of palmitoyl CoA formation was significantly greater than inhibition of arachidonoyl CoA formation in solubilized endothelial cell preparations. While 24-hour triacsin C treatment significantly reduced basal 6-keto synthesis, it had no effect on agonist-stimulated synthesis. The release of arachidonic acid metabolites was examined in [(3)H]arachidonate-labeled cells. Triacsin C treatment had no effect on basal or vasopressin-, angiotensin-II-, bradykinin- or ionomycin-induced release of radioactivity, but significantly reduced release in response to isoproterenol or phenylephrine. Expression of neither immunoreactive eNOS nor immunoreactive inducible nitric oxide synthetase (iNOS) was changed by triacsin C treatment, but the fraction of immunoreactive eNOS in the cytoplasm of treated cells was significantly greater as compared to vehicle control cells. Phorbol myristoyl acetate or fenofibrate significantly increased in vitro LCFACoAS activity, and significantly decreased the nitrite/eNOS ratio.
CONCLUSIONS: These data indicate that, while triacsin C can inhibit arachidonoyl CoA synthetase in endothelial cells, it does not increase the availability of endogenous substrate for basal or agonist-induced PGI(2) synthesis, nor does it enhance release of arachidonic acid or its metabolites. Copyright 2005 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15908751     DOI: 10.1159/000085847

Source DB:  PubMed          Journal:  J Vasc Res        ISSN: 1018-1172            Impact factor:   1.934


  2 in total

1.  Inhibition of long chain fatty acyl-CoA synthetase (ACSL) and ischemia reperfusion injury.

Authors:  Allan M Prior; Man Zhang; Nina Blakeman; Palika Datta; Hung Pham; Qian Chen; Lindon H Young; Margaret T Weis; Duy H Hua
Journal:  Bioorg Med Chem Lett       Date:  2014-01-13       Impact factor: 2.823

2.  Human intestinal acyl-CoA synthetase 5 is sensitive to the inhibitor triacsin C.

Authors:  Elke Kaemmerer; Anne Peuscher; Andrea Reinartz; Christian Liedtke; Ralf Weiskirchen; Jürgen Kopitz; Nikolaus Gassler
Journal:  World J Gastroenterol       Date:  2011-11-28       Impact factor: 5.742

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.